• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT2 抑制剂治疗遗传和获得性胰岛素抵抗：临床应用的注意事项。

SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use.

机构信息

Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

J Diabetes Investig. 2020 Nov;11(6):1431-1433. doi: 10.1111/jdi.13309. Epub 2020 Jul 1.

DOI:10.1111/jdi.13309
PMID:32469141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7610101/
Abstract

Administration of an sodium-glucose cotransporter 2 inhibitor to individuals with insulin resistance reduces the level of glucose disposal necessary to maintain glycemia as a result of the induced increase in urinary glucose excretion. The amount of insulin required for a certain level of glucose disposal, on which the evaluation of insulin resistance is usually based, might thus decrease even without amelioration of insulin resistance.

摘要

给予存在胰岛素抵抗的个体钠-葡萄糖共转运蛋白 2 抑制剂，可通过诱导尿糖排泄增加来降低维持血糖所需的葡萄糖处置水平。因此，即使没有改善胰岛素抵抗，用于特定葡萄糖处置水平的胰岛素量（通常基于该水平评估胰岛素抵抗）也可能减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ea0/7610101/097bbfc36ce3/JDI-11-1431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ea0/7610101/097bbfc36ce3/JDI-11-1431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ea0/7610101/097bbfc36ce3/JDI-11-1431-g001.jpg

相似文献

1
SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use.SGLT2 抑制剂治疗遗传和获得性胰岛素抵抗：临床应用的注意事项。
J Diabetes Investig. 2020 Nov;11(6):1431-1433. doi: 10.1111/jdi.13309. Epub 2020 Jul 1.
2
Recommendations on the Proper Use of SGLT2 Inhibitors.关于SGLT2抑制剂正确使用的建议。
J Diabetes Investig. 2020 Jan;11(1):257-261. doi: 10.1111/jdi.13160. Epub 2019 Nov 15.
3
Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance.钠-葡萄糖协同转运蛋白2抑制剂对胰腺β细胞功能的保护及胰岛素抵抗的降低作用。
J Diabetes. 2017 Mar;9(3):219-225. doi: 10.1111/1753-0407.12494. Epub 2016 Dec 1.
4
Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes.SGLT2抑制对糖尿病患者血压的作用机制
Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1679-1683. doi: 10.1016/j.dsx.2019.03.031. Epub 2019 Mar 17.
5
Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?钠-葡萄糖协同转运蛋白2抑制剂正在成为2型糖尿病的主流治疗方法吗？
Diabetes Metab Syndr. 2019 May-Jun;13(3):1893-1896. doi: 10.1016/j.dsx.2019.04.041. Epub 2019 Apr 23.
6
Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.SGLT2 抑制剂对 2 型糖尿病骨折和骨密度的影响：一项更新的荟萃分析。
Diabetes Metab Res Rev. 2019 Oct;35(7):e3170. doi: 10.1002/dmrr.3170. Epub 2019 May 15.
7
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂：治疗糖尿病肾病的新靶点。
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i13-i23. doi: 10.1093/ndt/gfz237.
8
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?钠-葡萄糖共转运蛋白 2 抑制剂：未来应治疗哪些慢性肾脏病患者？
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i48-i55. doi: 10.1093/ndt/gfz252.
9
SGLT2 inhibitors: molecular design and potential differences in effect.钠-葡萄糖协同转运蛋白2抑制剂：分子设计及效应的潜在差异
Kidney Int Suppl. 2011 Mar(120):S14-9. doi: 10.1038/ki.2010.511.
10
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭的影响：从病理生理学到临床效应
Int J Mol Sci. 2021 May 30;22(11):5863. doi: 10.3390/ijms22115863.

引用本文的文献

1
Paradoxical Inadequate Parathyroid Hormone Secretion Secondary to Severe Hypomagnesemia: A Review of the Literature.严重低镁血症继发的矛盾性甲状旁腺激素分泌不足：文献综述
Kidney Med. 2025 Jun 14;7(8):101046. doi: 10.1016/j.xkme.2025.101046. eCollection 2025 Aug.
2
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.心脏肿瘤学中心血管-肾脏-代谢综合征时代：从发病机制到预防与治疗
Cancers (Basel). 2025 Mar 30;17(7):1169. doi: 10.3390/cancers17071169.
3
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment.

本文引用的文献

1
Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.钠-葡萄糖共转运蛋白 2 抑制剂伊格列净治疗 A 型胰岛素抵抗综合征 1 例的长期疗效。
J Diabetes Investig. 2020 Sep;11(5):1363-1365. doi: 10.1111/jdi.13241. Epub 2020 Mar 20.
2
Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.钠-葡萄糖共转运蛋白 2 抑制剂治疗期间，通过高胰岛素-正葡萄糖钳夹分析测定的 HOMA-IR 与胰岛素敏感指数之间的关系。
Endocr J. 2020 May 28;67(5):501-507. doi: 10.1507/endocrj.EJ19-0445. Epub 2020 Feb 6.
3
SGLT2抑制剂在COVID-19中的应用：伞状综述、荟萃分析和贝叶斯敏感性评估。
Diseases. 2025 Feb 21;13(3):67. doi: 10.3390/diseases13030067.
4
The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者胰岛素抵抗和炎症的影响：一项回顾性研究
Medicina (Kaunas). 2025 Jan 24;61(2):209. doi: 10.3390/medicina61020209.
5
Insulin Resistance, a Risk Factor for Alzheimer's Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach.胰岛素抵抗：阿尔茨海默病的一个风险因素——病理机制及预防性治疗方法的新提议
Biomedicines. 2024 Aug 19;12(8):1888. doi: 10.3390/biomedicines12081888.
6
Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction.胰岛素抵抗/高胰岛素血症，射血分数保留的心力衰竭发生和恶化的被忽视的危险因素。
Biomedicines. 2024 Apr 4;12(4):806. doi: 10.3390/biomedicines12040806.
7
Diabetes mellitus with severe insulin resistance in a young male patient with a heterozygous pathogenic frameshift variant.一名年轻男性患者患有杂合致病性移码变异，伴有严重胰岛素抵抗的糖尿病。
Clin Pediatr Endocrinol. 2024;33(2):87-93. doi: 10.1297/cpe.2023-0081. Epub 2024 Feb 23.
8
Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated.胰岛素抵抗/高胰岛素血症：一个长期以来被低估的重要心血管危险因素。
Front Cardiovasc Med. 2024 Mar 13;11:1380506. doi: 10.3389/fcvm.2024.1380506. eCollection 2024.
9
The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment.胰岛素抵抗/高胰岛素血症对慢性心力衰竭的负面影响及其筛查与治疗的潜在益处
Biomedicines. 2023 Oct 30;11(11):2928. doi: 10.3390/biomedicines11112928.
10
ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents.《国际儿童青少年糖尿病研究学会（ISPAD）2022年临床实践共识指南：儿童和青少年单基因糖尿病的诊断与管理》
Pediatr Diabetes. 2022 Dec;23(8):1188-1211. doi: 10.1111/pedi.13426.
Clinical characteristics of insulin resistance syndromes: A nationwide survey in Japan.
胰岛素抵抗综合征的临床特征：日本全国性调查。
J Diabetes Investig. 2020 May;11(3):603-616. doi: 10.1111/jdi.13171. Epub 2019 Dec 5.
4
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净可减少肝脏脂肪，但不影响组织胰岛素敏感性：在 2 型糖尿病患者中进行的为期 8 周的随机、双盲、安慰剂对照研究。
Diabetes Care. 2019 May;42(5):931-937. doi: 10.2337/dc18-1569. Epub 2019 Mar 18.
5
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).伊格列净对血糖控制、食欲及其相关激素的影响：一项前瞻性、多中心、开放标签研究（SOAR-KOBE 研究）。
J Diabetes Investig. 2019 Sep;10(5):1254-1261. doi: 10.1111/jdi.13015. Epub 2019 Mar 28.
6
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.伊格列净，一种钠-葡萄糖共转运蛋白 2 抑制剂，可降低日本 2 型糖尿病患者胰岛素治疗时的体重和脂肪量，但不减少肌肉量：一项随机临床试验。
J Diabetes Investig. 2019 Jul;10(4):1012-1021. doi: 10.1111/jdi.12985. Epub 2019 Jan 21.
7
Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.使用钠-葡萄糖共转运蛋白 2 抑制剂治疗 1 例由于 PIK3R1 突变引起的严重胰岛素抵抗病例。
J Diabetes Investig. 2018 Sep;9(5):1224-1227. doi: 10.1111/jdi.12825. Epub 2018 Mar 25.
8
Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.格列美脲治疗胰岛素受体基因突变致 A 型胰岛素抵抗综合征 1 例
J Diabetes Investig. 2018 Sep;9(5):1075-1083. doi: 10.1111/jdi.12824. Epub 2018 Mar 24.
9
Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.恩格列净可降低伴有胰岛素抵抗的 2 型糖尿病患者的残粒样颗粒胆固醇。
J Diabetes Investig. 2018 Jul;9(4):870-874. doi: 10.1111/jdi.12781. Epub 2017 Dec 27.
10
Case of lipoatrophic diabetes induced by juvenile dermatomyositis.青少年皮肌炎诱发脂肪萎缩性糖尿病病例。
J Diabetes Investig. 2017 Sep 12;9(3):632-5. doi: 10.1111/jdi.12745.